Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. Schmid P, et al. Among authors: bogenrieder t. Breast Cancer Res. 2021 Jan 15;23(1):8. doi: 10.1186/s13058-020-01382-8. Breast Cancer Res. 2021. PMID: 33451345 Free PMC article. Clinical Trial.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: bogenrieder t. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.
Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, Wang CC, Seto T, Huang DC, Jung HH, Hsu MC, Bogenrieder T, Lin CC. Park K, et al. Among authors: bogenrieder t. JTO Clin Res Rep. 2021 Jul 10;2(9):100206. doi: 10.1016/j.jtocrr.2021.100206. eCollection 2021 Sep. JTO Clin Res Rep. 2021. PMID: 34590052 Free PMC article.
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, Baumgartinger R, Adam PJ, Solca F, Kraut N, Nguyen HM, Corey E, Liu G, Sprenger CC, Plymate SR, Bogenrieder T. Weyer-Czernilofsky U, et al. Among authors: bogenrieder t. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. doi: 10.1158/1535-7163.MCT-19-0378. Epub 2020 Feb 13. Mol Cancer Ther. 2020. PMID: 32054790 Free PMC article.
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
Rieunier G, Wu X, Harris LE, Mills JV, Nandakumar A, Colling L, Seraia E, Hatch SB, Ebner DV, Folkes LK, Weyer-Czernilofsky U, Bogenrieder T, Ryan AJ, Macaulay VM. Rieunier G, et al. Among authors: bogenrieder t. Cancer Res. 2021 Apr 15;81(8):2128-2141. doi: 10.1158/0008-5472.CAN-20-2860. Epub 2021 Jan 28. Cancer Res. 2021. PMID: 33509941
Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.
Aleksic T, Gray N, Wu X, Rieunier G, Osher E, Mills J, Verrill C, Bryant RJ, Han C, Hutchinson K, Lambert AG, Kumar R, Hamdy FC, Weyer-Czernilofsky U, Sanderson MP, Bogenrieder T, Taylor S, Macaulay VM. Aleksic T, et al. Among authors: bogenrieder t. Cancer Res. 2018 Jul 1;78(13):3497-3509. doi: 10.1158/0008-5472.CAN-17-3498. Epub 2018 May 7. Cancer Res. 2018. PMID: 29735545 Free PMC article.
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W, Sehouli J; North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer. Koensgen D, et al. Among authors: bogenrieder t. Cancer Chemother Pharmacol. 2008 Aug;62(3):393-400. doi: 10.1007/s00280-007-0617-2. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922272 Clinical Trial.
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.
Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A. Ireland L, et al. Among authors: bogenrieder t. Cancer Res. 2016 Dec 1;76(23):6851-6863. doi: 10.1158/0008-5472.CAN-16-1201. Epub 2016 Oct 14. Cancer Res. 2016. PMID: 27742686 Free PMC article.
56 results